

AI Safety Meets Biological Heterogeneity

Why some patients don't respond to GLP-1 drugs reveals a deeper flaw in predictive systems.

Swipe for insights →

THE DATA

10–15%

Non-responders to GLP-1 drugs

Despite widespread efficacy, a consistent subset of patients shows minimal or no weight loss from GLP-1 medications.

This range—10–15%—represents a critical failure point in what is otherwise a precision medicine breakthrough. The inconsistency challenges the assumption that biological interventions can be universally optimized through data-driven models. If AI systems are trained on aggregate responses, they risk reinforcing bias by overlooking the very patients who deviate from the norm.

Source: Nature · Published September 24, 2026

https://www.nature.com/articles/d41586-026-03020-3?error=cookies_not_supported&code=999509f1-1bea-4514-ab3c-b09b6e35c719

01


Predictive AI Fails Where Biology Is Chaotic

The 10–15% non-response rate reveals a systemic blind spot: AI models trained on average outcomes cannot account for biological heterogeneity. When AI systems assume uniformity in response, they fail to detect the emergent patterns in outlier populations. This is not a data deficiency—it is a modeling failure rooted in overconfidence in statistical averages.

02

Ethics of Exclusion in Personalized Systems

If AI-driven healthcare excludes 1 in 7 patients by design, it violates the core principle of equitable access. The fact that women respond more strongly to GLP-1 drugs due to hormonal interactions suggests that sex-based biological differences are not just confounders—they are essential variables. AI systems that ignore such stratification risk entrenching inequity under the guise of 'efficiency'.



MIT, Nvidia, Google & IBM-Trained. Cross Domain-Expert: Quantum, AI, Ethics, Sovereignty, Intelligence, Philanthropy.
Solepoint Planning. VUI AI Cloud Architect. AI Certifications Development. Quant/AI Instructor. Castor Venture Club Member.
Associate Broker.

George Arnold Alexander III, MPA

Director, ALEX Companies

Associate Broker, Alexander Tiffany Southwest, LLC dba ALEX.realestate, et.al.

Texas License #574878-B · Broker License #565194-BB

Broker, ALEX Real Estate · North Carolina License #367733

Independent Broker, ALEX Real Estate · Colorado License #II.100112456

george@alex.realestate · +1 713.918.9951



ALEX Intelligence
deep intelligence

ALEX Real Estate
genius real estate

ALEX Advisory
uncontested strategy

ALEX Cares
purposeful philanthropy

